Business Wire

AlertEnterprise Looks to Transform Physical Security with Reveal of New Security AI Chatbot Powered by ChatGPT

28.2.2023 17:00:00 EET | Business Wire | Press release

Share

AlertEnterprise, Inc., the leading cyber-physical security convergence software company, today revealed the launch of its first-ever Guardian AI Chatbot powered by OpenAI ChatGPT. The company will debut the AI Chatbot globally end of March at the ASIS Europe and ISC West trade events.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230228005630/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

The Guardian AI Chatbot has been trained on ChatGPT’s most recent content and prompts and can understand and interpret text and voice using a natural language processing (NLP) engine. The Chatbot can quickly answer a range of questions related to physical access, identity access management, visitor management, door reader analytics, and security and safety reporting. (Graphic: Business Wire)

The Guardian AI Chatbot is developed with the world-renowned GPT-3 platform created by OpenAI and is designed to instantly deliver security operators the physical access and security insights that matter most with quick questions and prompts.

“Physical security and access control systems have always contained a tremendous wealth of data but, until now, accessing it was a tedious and manual process,” said Yogesh Ailawadi, SVP Product and Solutions Engineering at AlertEnterprise. “Our Guardian AI Chatbot is poised to redefine the security operator’s experience, increasing their productivity by over 100 times with instant and actionable insights for not only risk mitigation but real business value.”

Mr. Ailawadi noted that the Guardian AI Chatbot is part of the launch of AlertEnterprise’s next-gen AI technology and is completely integrated throughout the Guardian platform.

Get powerful answers in an instant

The Guardian AI Chatbot has been trained on ChatGPT’s most recent content and prompts and can understand and interpret text and voice using a natural language processing (NLP) engine.

The Chatbot can quickly answer a range of questions related to physical access, identity access management, visitor management, door reader analytics, and security and safety reporting.

Some examples are:

  • “Guardian, how many people are on the Trading floor?”
  • “Guardian, how many employees and visitors are in the Data Center?”
  • “Guardian, how many new employee badges did we issue last month?”
  • “Guardian, show me upcoming employee training expirations for restricted area access.”

Drive costs down. Boost employee efficiency.

Using Guardian and its AI Chatbot, CSO and CISO’s can exponentially boost their team’s efficiency by automating tedious tasks and freeing up time to focus on more critical responsibilities. Guardian also leverages a company’s current security investments by connecting to most leading access control vendors and over 200 out-of-the-box connectors to HR, IT and OT systems. And if the organization has a complex mix of access control systems, Guardian connects to and consolidates them all under one platform.

AlertEnterprise founder and CEO Jasvir Gill says there’s no better time for CSO and CISO’s to invest in hyper-efficiency boosting AI platforms like Guardian. “Despite economic headwinds, the world’s most forward-looking CSO and CISO’s are accelerating security digital transformation. With Guardian’s deep forensics and AI data-driven insights, CSO and CISO’s can transform their access control from the stone age to the digital age—making every part of their SOC more automated, expeditious and cost effective, and ultimately the organization more secure. That’s why I view the AlertEnterprise Guardian platform as a deflationary fighting force for companies today.”

To see a live demonstration of the Guardian AI Chatbot, visit AlertEnterprise at Stand C5 at ASIS Europe in Rotterdam, NL, and Booth #13115 at ISC West in Las Vegas, USA.

AlertEnterprise

At AlertEnterprise, cyber-physical identity and trust are at the center of everything we do. Our mission is to bring people, processes, data and technology together in a unique way to help organizations protect what matters most. We call it security convergence. And we develop game-changing security convergence solutions that deliver identity governance, access management, security intelligence and compliance validation across enterprise IT, HR, cyber and physical security environments.

AlertEnterprise is committed to using AI in a responsible and ethical manner. We recognize the importance of protecting customer data and safeguarding against potential misuse of AI technology. As such, we have implemented strict policies and procedures to ensure the ethical use of AI and to protect the privacy and security of our customers' data. We believe that transparency and accountability are critical in this regard and remain dedicated to upholding these values throughout our development and operations.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Willem Ryan – Senior Vice President of Marketing and Communications
Email: media@alertenterprise.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 21:00:00 EET | Press release

Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. “These efficacy and safety results show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance, highlighting the potential of zasoc

Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 21:00:00 EET | Press release

Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT). “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical ben

AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 17:00:00 EET | Press release

Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260328320362/en/ Atopic dermatitis is the most common inflammatory skin disorder in children, yet treatment options in the moderate-to-severe pediatric setting are limited.5 The disease can have a significant impact on quality of life for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school and relationships.5-8 “Atopic dermatitis can affect many aspects of children’s lives including schoolwork, emotional development

Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 21:56:00 EET | Press release

Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti

Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 19:46:00 EET | Press release

Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye